MEDIWOUND LTD (MDWD)
IL0011316309 - Common Stock
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed...
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips MediWound (NASDAQ:MDWD) just reported results for the fourth quarter of 2023.Me...
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
$19 million revenue in 2023; $24 million projected revenue in 2024NexoBrid® commercially launched in U.S., Japan, IndiaPotential blockbuster EscharEx® to...
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time
MediWound stock climbs 9% on Phase 2 data for wound care treatment (NASDAQ:MDWD)
Shares of MediWound (MDWD) climbed 9% Monday after the Israeli company reported positive Phase 2 data for its chronic wound treatment EscharEx. The study was a
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU)
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation...
MediWound to Participate in Two Upcoming Investor Conferences
MediWound to Participate in Two Upcoming Investor Conferences
YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation...
FDA accepts MediWound application for NexoBrid pediatric approval (NASDAQ:MDWD)
MediWound (MDWD) said the FDA has accepted its supplemental application to have its product NexoBrid approved for the treatment of burns in pediatric patients. Read more here.
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S. NexoBrid is already...
MediWound wins DoD funding to develop NexoBrid for U.S. Army (NASDAQ:MDWD)
The U.S. Department of Defense awards MediWound $6.7M to develop NexoBrid as a non-surgical burn treatment for the U.S. Read more here.
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million...
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement...
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx® Phase III study...
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation...
MediWound to Report Third Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time
MediWound to Report Third Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time...
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages ...
MediWound collaborates with Polymedics for Nexobrid distribution in Europe (NASDAQ:MDWD)
MediWound partners with PolyMedics Innovations for the promotion of NexoBrid in Germany, Austria, Belgium, the Netherlands, and Luxembourg, aiming to boost...
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
MediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
MediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers...
MediWound Deploys NexoBrid® for Emergency Supply
MediWound Deploys NexoBrid® for Emergency Supply
YAVNE, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation...